Manipulating the NF-κB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 2163-2177

  Ortega, Ryan A ^a,b   Barham, Whitney ^b   Sharman, Kavya ^c   Tikhomirov, Oleg ^b   Giorgio, Todd D ^a,b   Yull, Fiona E ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Cancer immunology; Nanotechnology; RNAi; Targeted nanoparticles

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NANOPARTICLE; SMALL INTERFERING RNA; CXCL9 CHEMOKINE; CXCL9 PROTEIN, MOUSE; I KAPPA B KINASE ALPHA; LIPID; LIPOFECTAMINE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; GENE TARGETING; IMMUNOSTIMULATION; MACROPHAGE; MACROPHAGE CULTURE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BONE MARROW CELL; CYTOLOGY; DRUG EFFECTS; FEMALE; GENETICS; GLYCOSYLATION; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NANOMEDICINE; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; CHEMOKINE CXCL9; FEMALE; GLYCOSYLATION; LIPIDS; MACROPHAGES; MICE, KNOCKOUT; MICE, TRANSGENIC; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84969534980     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S93483     Document Type: Article

References (63)

1. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008;222:357–368.
2. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39:49–60.
3. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-κB signaling pathways. Nat Immunol. 2011;12:695–708.
4. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51.
5. DeNardo DG, Brennan DJ, Rexhepaj E, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67.
6. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555.
7. Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol. 2009;174:1048–1064.
8. Greten FR, Eckmann L, Greten TF, et al. Ikkbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–296.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
10. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006;211:487–501.
11. Baj-Krzyworzeka M, Baran J, Szatanek R, Stankiewicz D, Siedlar M, Zembala M. Prevention and reversal of tumor cell-induced monocyte deactivation by cytokines, purified protein derivative (Ppd), and anti-IL-10 antibody. Cancer Immun. 2004;4:8.
12. Sica A, Saccani A, Bottazzi B, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000;164:762–767.
13. DeNardo DG, Barreto JB, Andreu P, et al. Cd4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91–102.
14. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113–2126.
15. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064–5066.
16. Qian B, Deng Y, Im JH, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One. 2009;4:e6562.
17. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727–740.
18. Stathopoulos GT, Sherrill TP, Han W, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008;6:364–371.
19. Zaynagetdinov R, Sherrill TP, Polosukhin VV, et al. A critical role for macrophages in promotion of urethane-induced lung carcinogenesis. J Immunol. 2011;187:5703–5711.
20. Sun SC. The noncanonical NF-κB pathway. Immunol Rev. 2012;246:125–140.
21. Nathan C, Brukner L, Kaplan G, Unkeless J, Cohn Z. Role of activated macrophages in antibody-dependent lysis of tumor cells. J Exp Med. 1980;152:183–197.
22. Nathan C, Cohn Z. Role of oxygen-dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages. J Exp Med. 1980;152:198–208.
23. Connelly L, Barham W, Onishko HM, et al. NF-kappaB activation within macrophages leads to an anti-tumor phenotype in a mammary tumor lung metastasis model. Breast Cancer Res. 2011;13:R83.
24. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, Hobbs AJ. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem. 2003;278:26480–26487.
25. Bellas RE, FitzGerald MJ, Fausto N, Sonenshein GE. Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am J Pathol. 1997;151:891–896.
26. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011;12:715–723.
27. Makarov SS. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today. 2000;6:441–448.
28. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–288.
29. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811.
30. Behr JP. The proton sponge: a trick to enter cells that viruses did not exploit. Chimia. 1997;51:34–36.
31. Convertine AJ, Diab C, Prieve M, et al. pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules. 2010;11:2904–2911.
32. Evans BC, Nelson CE, Yu SS, et al. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp. 2013;73:e50166.
33. Boyer C, Bulmus V, Davis TP, Ladmiral V, Liu J, Perrier S. Bioapplications of raft polymerization. Chem Rev. 2009;109:5402–5436.
34. Allavena P, Chieppa M, Bianchi G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol. 2010;2010:547179.
35. Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116:2132–2141.
36. Stahl PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol. 1998;10:50–55.
37. Yu SS, Lau CM, Barham WJ, et al. Macrophage-specific RNA interference targeting via “click”, mannosylated polymeric micelles. Mol Pharm. 2013;10:975–987.
38. Ortega RA, Barham WJ, Kumar B, et al. Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale. 2015;7:500–510.
39. Hagemann T, Lawrence T, McNeish I, et al. “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med. 2008;205:1261–1268.
40. Yang J, Hawkins OE, Barham W, et al. Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response. Cancer Res. 2014;74:7274–7284.
41. Everhart MB, Han W, Sherrill TP, et al. Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol. 2006;176:4995–5005.
42. Porcheray F, Viaud S, Rimaniol AC, et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol. 2005;142:481–489.
43. Han W, Joo M, Everhart MB, Christman JW, Yull FE, Blackwell TS. Myeloid cells control termination of lung inflammation through the NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol. 2009;296:L320–L327.
44. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–591.
45. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22:231–237.
46. Cao S, Zhang X, Edwards JP, Mosser DM. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem. 2006;281:26041–26050.
47. Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappa B loop. Nat Cell Biol. 1999;1:227–233.
48. Wang Y, Mo X, Piper MG, et al. M-CSF induces monocyte survival by activating NF-κB p65 phosphorylation at Ser276 via protein kinase C. PLoS One. 2011;6:e28081.
49. Fuseler JW, Merrill DM, Rogers JA, Grisham MB, Wolf RE. Analysis and quantitation of NF-kappa B nuclear translocation in tumor necrosis factor alpha (TNF-alpha) activated vascular endothelial cells. Microsc Microanal. 2006;12:269–276.
50. Roos C, Wicovsky A, Muller N, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol. 2010;185:1593–1605.
51. Chattopadhyay U, Bhattacharyya S, Chakrabarty NG. Tumor associated macrophage mediated lysis of autologous tumor cells. Neoplasma. 1986;33:157–165.
52. Cox GW. Assay for macrophage-mediated anti-tumor cytotoxicity. Curr Protoc Immunol. 2001;Chapter 14:Unit147.
53. Fiani ML, Beitz J, Turvy D, Blum JS, Stahl PD. Regulation of mannose receptor synthesis and turnover in mouse J774 macrophages. J Leukoc Biol. 1998;64:85–91.
54. Ezekowitz RA, Sastry K, Bailly P, Warner A. Molecular characterization of the human macrophage mannose receptor: demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells. J Exp Med. 1990;172:1785–1794.
55. Müller M, Carter S, Hofer MJ, Campbell IL. Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity – a tale of conflict and conundrum. Neuropathol Appl Neurobiol. 2010;36:368–387.
56. Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J. Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther. 2001;8:282–290.
57. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse renca tumor. J Immunol. 1998;161:927–932.
58. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3:666–675.
59. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686.
60. Armstrong L, Jordan N, Millar A. Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes. Thorax. 1996;51:143–149.
61. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for P50. Clin Exp Immunol. 2004;135:64–73.
62. Smale ST. Hierarchies of NF-κB btarget-gene regulation. Nat Immunol. 2011;12:689–694.
63. Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170–181.